Latest news with #SoC
Yahoo
3 days ago
- Business
- Yahoo
QuickLogic to Exhibit at Chips to Systems Conference (DAC) 2025
SAN JOSE, Calif., June 18, 2025 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK), a developer of embedded FPGA (eFPGA) Hard IP, ruggedized FPGAs, and endpoint AI solutions, today announced it will exhibit at the 2025 Chips to Systems Conference (DAC) in San Francisco. Visit Booth #2222 to explore QuickLogic's advanced eFPGA Hard IP and chiplet solutions designed to help accelerate SoC and ASIC development and learn how QuickLogic's silicon-proven eFPGA Hard IP enables post-manufacturing flexibility, helping designers reduce time-to-market and cost while meeting performance, power, and area (PPA) goals. You will also discover our chiplet solutions, featuring validated, interoperable blocks backed by Universal PHY™ and a robust ecosystem—making heterogeneous integration faster, easier, and more efficient. Event Details:When: June 23–25, 2025Where: Booth #2222 (Moscone West, 2nd Floor)Website: Come see us at DAC 2025 to learn how QuickLogic's eFPGA IP and chiplet-ready solutions can support your design goals with unmatched flexibility and efficiency. About QuickLogic QuickLogic Corporation is a fabless semiconductor company that specializes in eFPGA Hard IP, discrete FPGAs, and endpoint AI solutions. The company's unique technology, combined with open-source development tools, enables highly customizable and low-power silicon solutions for aerospace and defense, industrial, consumer, and edge computing markets. For more information, visit QuickLogic and logo are registered trademarks of QuickLogic. All other trademarks are the property of their respective holders and should be treated as such. View original content to download multimedia: SOURCE QuickLogic Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
South China Morning Post
5 days ago
- Automotive
- South China Morning Post
SemiDrive to supply EV cockpit chips to European carmaker as Chinese firms go global
Chinese automotive chip firm SemiDrive will start supplying its cockpit system-on-a-chip (SoC) to an undisclosed European carmaker late next year, marking its first collaboration on the continent to push for global sales, a senior executive said. Advertisement The chips would be used in several of the carmaker's models including sedans and SUVs produced and sold in the Europe, Middle East and Africa region, general manager Eugene Wang said. The vehicles were expected to feature its X9 SoC, which integrates high-performance CPUs, GPUs, AI accelerators and video processors designed for advanced cockpit applications, he added. 'It will be the first time we supply our chips to foreign OEMs [original equipment manufacturers] in their mass-produced vehicles overseas,' Wang said on the sidelines of the four-day International Automotive & Supply Chain Expo in Hong Kong. 'Striving to be a top global chip supplier, we need to expand from the China market to the global market.' SemiDrive, founded in 2018, specialises in developing high-performance automotive-grade chips for smart cockpits and microcontroller units (MCUs). SAIC Motor, Sequoia Capital, Walden International and Matrix Partners participated in its fundraisings since 2019. The firm is based in Nanjing in the eastern province of Jiangsu. It has produced four chip series to date, including the X9, the smart-driving chip V9, the central-gateway chip G9 and the high-performance MCU E3. The firm has supplied more than 8 million chips since 2021, used in more than 100 models produced by Chery Auto, Chang'an Auto, SAIC Motor, GAC, BAIC and Li Auto, Wang said. Advertisement Fewer than 10 per cent of these chips were used in vehicles bound for export markets, Wang said. As such, the tie-up with the European carmaker represented a significant milestone in its global expansion plans as the company aims to 'connect with foreign carmakers and reach a bigger marketplace', he added.
GSM Arena
5 days ago
- GSM Arena
MediaTek Dimensity 9500 details revealed through Geekbench scoresheet
MediaTek's next-gen flagship SoC, the Dimensity 9500, is rumored to arrive earlier than usual to beat Qualcomm's Snapdragon 8 Elite 2 to the market. So we are looking at early to mid-September debut. MediaTek's Dimensity 9500 processor spotted on Geekbench with Mali-G1-Ultra MC12 Dimensity 9500 Chipset/SoC4 Cores @ 2.23 GHz Gelas3 Cores @ 3.03 GHz Alto1 Core @ 3.23 GHz Travis X930🎮 Mali-G1-Ultra MC12 1MHz frequency alps k6993v1_64 — Abhishek Yadav (@yabhishekhd) June 16, 2025 Now that the alleged Dimensity 9500 has gone through Geekbench, which has filled us in on the specs. The chip will feature 1x Travis X930 main core clocked at 3.23 GHz, 3x Alto cores running at 3.03 GHz and 4x Gelas cores ticking at 2.23 GHz. The Mali-G1-Ultra MC12 GPU will take care of the graphics, clocked at 1000 MHz. The info from Geekbench seems to be aligned with the April leak, all eight cores. The only discrepancy is the GPU, which was thought to be Immoralis-Drage. A previous report also suggested the new NPU will be significantly more powerful, capable of delivering 100 TOPS. We will likely start seeing the chipset appear on various benchmark databases in the coming weeks and months, so stay tuned.
Business Wire
05-06-2025
- Health
- Business Wire
Intradermal Vaccination over Intramuscular Standard of Care
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial. 1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. "This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio." Share This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022, 2 it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support, 3 while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date. 4 The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated: Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used. Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery, 4 which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period. Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response. 'This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio,' said Paul LaBarre, Vice President Global Business Development, PharmaJet. 'With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.' Refer to Instructions for Use to ensure safe injections and to review risks. 1 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial, Vaccines,16 May 2025, 13(5), p.533 2 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025) 3 Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018. 4 Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis ® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI's goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026.
Yahoo
05-06-2025
- Health
- Yahoo
Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care
Substantial Improvements in Coverage of IPV2. Vaccine coverage of the second dose of inactivated polio vaccine (IPV2) administered with Tropis ID increased by 11.2% compared to the standard of care (SoC, full dose delivered by needle and syringe intramuscular delivery). On a relative basis, the odds of receiving 2 doses of IPV are doubled when using Tropis ID. Preferred by Vast Majority of Healthcare Workers. Needle-free Tropis ID was the preferred method of vaccination for routine immunization (RI) as reported by 97% of healthcare workers surveyed, who cited that, compared to the SoC, Tropis ID was (i) easier to use (95%), and (ii) children experienced less discomfort (94%). Significant Cost Reductions. Incremental savings with needle-free could range from US$0.07 to US$1.00 per dose, with up to 47% total immunization cost savings compared to the SoC in a full-scale scenario. This equates to a potential savings of ~US$50 million over a 5-year period using Tropis ID for the Nigeria immunization program. GOLDEN, Colo., June 05, 2025--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial.1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022,2 it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support,3 while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date.4 The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated: Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used. Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery,4 which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period. Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response. "This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio," said Paul LaBarre, Vice President Global Business Development, PharmaJet. "With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs." Refer to Instructions for Use to ensure safe injections and to review risks. 1 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.5332 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025)3 Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018.4 Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About The Global Polio Eradication Strategy (GPEI) In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI's goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026. View source version on Contacts Nancy 1-888-900-4321 Option 3 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
